Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: Focus on drugs potentially effective in Alzheimer's disease

Biochemical Pharmacology

Volumn 55, Issue 10, 1998, Pages 1733-1737

  Costagli, Chiara ^a   Galli, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholinesterase; Anticholineste rase agents; Aryl acylamidase; Butyrylcholinesterase; Serotonin; Tacrine

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; ACETYLCHOLINESTERASE; ARYL ACYLAMIDASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DYFLOS; EDROPHONIUM; GALLAMINE; HEPTYLPHYSOSTIGMINE; HUPERZINE A; INDOLEAMINE; ISO OMPA; NEOSTIGMINE; PHYSOSTIGMINE; PHYSOSTIGMINE DERIVATIVE; PROPIDIUM IODIDE; SEROTONIN; SEROTONIN DERIVATIVE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CHOLINESTERASE INHIBITION; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG POTENCY; EEL; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HORSE; HYDROLYSIS; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMIDOHYDROLASES; ANIMALS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ELECTROPHORUS; HUMANS;

EID: 0032524964     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00676-X     Document Type: Article

References (21)

1. Balasubramanian AS, Bhanumathy CD. Noncholinergic functions of cholinesterases. FASEB J. 7:1993;1354-1358.
2. Small DH, Michaelson S, Sberna G. Non-classical actions of cholinesterases role in cellular differentiation, tumorigenesis and Alzheimer's disease . Neurochem Int. 28:1996;453-483.
3. Fujimoto D. Serotonin-sensitive aryl acylamidase activity of acetylcholinesterase. FEBS Lett. 72:1976;121-123.
4. George ST, Balasubramanian AS. The identity of the serotonin-sensitive aryl acylamidase with acetylcholinesterase from human erythrocytes, sheep basal ganglia and electric eel. Eur J Biochem. 111:1980;511-524.
5. George ST, Balasubramanian AS. The aryl acylamidase and their relationship to cholinesterase in human serum, erythrocyte and liver. Eur J Biochem. 121:1981;177-186.
6. Checler F, Grassi J, Vincent J-P. Cholinesterases display genuine arylacylamidase activity but are totally devoid of intrinsic peptidase activities. J Neurochem. 62:1994;756-763.
7. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid beta-peptides into Alzheimer's fibrils possible role of the peripheral site of the enzyme . Neuron. 16:1996;881-891.
8. Navaratnam DS, Priddle JD, McDonald B, Esiri MM, Robinson JR, Smith AD. Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. Lancet. 337:1991;447-449.
9. Ogane N, Giacobini E, Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res. 589:1992;307-312.
10. Giacobini E. The second generation of cholinesterase inhibitors pharmacological aspects . Becker R, Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;247-262 Birkhauser, Boston.
11. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA. 268:1992;2523-2529.
12. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res. 37:1994;777-787.
13. Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci. 7:1996;41-49.
14. Wright CI, Geula C, Mesulam M-M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. Proc Natl Acad Sci USA. 90:1992;683-686.
15. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves application to bioassay, radioligand assay and physiological dose-response curves . Am J Physiol. 235:1978;E97-E102.
16. Dixon M, Webb EC. Enzyme inhibition and activation. Dixon M, Webb EC. Enzymes. 1979;332-467 Longman, London.
17. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7:1961;88-95.
18. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, Tanaka T. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol. 33:1993;1086-1091.
19. Unni LK, Radcliffe J, Latham G, Sunderland T, Martinez R, Potter W, Becker RE. Oral administration of heptylphysostigmine in healthy volunteers a preliminary study . Methods Find Exp Clin Pharmacol. 16:1994;373-376.
20. Zhi QX, Yi FH, Xi CT. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport. 6:1995;2221-2224.
21. Taylor P, Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry. 9:1975;1989-1997.